BioVector? 4T1-Taxol Paclitaxel-Resistant Mouse Mammary Carcinoma Cell Line / 4T1-Taxol 小鼠乳腺癌紫杉醇耐藥特異性細胞株

一 產(chǎn)品基本信息與細胞生物學背景

• 細胞名稱：4T1-Taxol（亦稱 4T1/PTX，4T1-PR）。

• 物種與組織來源：小鼠（Mus musculus），源自 BALB/c 小鼠自發(fā)性乳腺癌（4T1 親本細胞），經(jīng)體外高濃度紫杉醇（Taxol/Paclitaxel）階梯遞增壓力誘導篩選建立的耐藥亞系。

• 細胞系建立背景（耐藥株的衍生）：4T1 親本細胞是國際公認的、惡性程度極高且極具侵襲性的小鼠三陰性乳腺癌（TNBC）同系移植模型。紫杉醇（Taxol）作為臨床針對乳腺癌的一線微管穩(wěn)定類化療藥物，極易在治療中后期誘發(fā)獲得性耐藥?？蒲腥藛T通過在 4T1 親本細胞的日常培養(yǎng)基中，連續(xù)數(shù)月、從極低劑量（如幾納摩爾）階梯式遞增添加紫杉醇進行持續(xù)的體外生存壓力篩選（Stepwise escalating drug selection method），最終促使特定抗性克隆存活。在對其進行單克隆富集擴增及耐藥指數(shù)（RI）鑒定后，鎖定了這株具備高穩(wěn)定紫杉醇耐藥表型的衍生亞系 4T1-Taxol。

• 核心表型與耐藥機理特征：

  • 耐藥譜系表征：相較于親本 4T1 細胞，4T1-Taxol 的半抑制濃度（IC50）飆升了數(shù)十倍甚至上百倍。對紫杉醇引發(fā)的微管束聚合穩(wěn)定、有絲分裂阻滯及后續(xù)的凋亡級聯(lián)反應（Apoptosis cascade）表現(xiàn)出強烈的抵抗性。

  • 形態(tài)學改變：貼壁生長。在倒置顯微鏡下，該耐藥亞系維持了基本的上皮樣（Epithelial-like）形態(tài)，但相較于親本，其胞體通常略微增大、鋪展、拉長，細胞骨架發(fā)生重塑，甚至細胞核在 DAPI 染色下表現(xiàn)出特征性的異質(zhì)性肥大。

  • 耐藥分子機制：細胞內(nèi)部高度激活了藥物外排泵（如 P-糖蛋白 P-gp/MDR1/ABCB1）、發(fā)生了微管蛋白異型體（如 β-tubulin 突變或高表達）改變，或者選擇性激活了 HER2/β-catenin/c-Myc 等抗凋亡增殖通路，使其能夠在高濃度藥物環(huán)境中完美繞過細胞周期監(jiān)控。

• 生物安全級別：1級（BSL-1）。

二 核心科研價值與轉(zhuǎn)化醫(yī)學應用

4T1-Taxol 克服了人源耐藥模型無法在免疫健全小鼠體內(nèi)成瘤的瓶頸，在腫瘤藥理學和轉(zhuǎn)化醫(yī)學研究中扮演著不可替代的角色：

1. 化療耐藥逆轉(zhuǎn)劑（Chemoresistance Reversers）的體外高通量篩選：4T1-Taxol 是尋找“紫杉醇增敏劑”的標準底盤?？蒲腥藛T通常將其作為靶板，篩選新型小分子激酶抑制劑、MDR1 外排泵阻斷劑、中藥天然提取物（如 EGCG 等）是否能與紫杉醇聯(lián)合，重新恢復該耐藥株對微管靶向化療的敏感性。

2. 同系免疫健全耐藥小鼠模型構(gòu)建（Syngeneic Taxol-Resistant CDX Model）：這是該細胞系最核心的戰(zhàn)略價值。將 4T1-Taxol 接種到免疫健全的 BALB/c 雌鼠的原位乳腺脂肪墊（Mammary fat pad）或皮下后，其成瘤率高達 100%。它可以完美模擬臨床上“晚期三陰性乳腺癌患者對紫杉醇化療耐藥、腫瘤持續(xù)生長及全身廣泛性轉(zhuǎn)移”的極其復雜的病理微環(huán)境。

3. 耐藥狀態(tài)下的腫瘤轉(zhuǎn)移（Metastasis）與腫瘤免疫微環(huán)境（TME）探討：4T1 親本本身即具有極強的自發(fā)轉(zhuǎn)移（肺、肝、腦、骨等）能力。通過 4T1-Taxol 模型，研究者能深度探究：乳腺癌細胞在對紫杉醇耐藥后，其長途遷移能力、上皮-間充質(zhì)轉(zhuǎn)化（EMT）活性是否發(fā)生進一步進化；以及耐藥腫瘤在體內(nèi)如何通過耗竭 T 細胞、富集 MDSCs（髓系來源抑制細胞），來構(gòu)建更為頑固的免疫逃逸微環(huán)境。

三 實驗室細胞復蘇、貼壁常規(guī)培養(yǎng)、傳代與保存標準步驟

4T1-Taxol 細胞生長極為兇猛，其細胞倍增時間短，對營養(yǎng)消耗速度驚人。在培養(yǎng)過程中，最大的控制核心是維持其耐藥表型的穩(wěn)定性。

1. 培養(yǎng)基配置與耐藥壓力維持

• 基礎(chǔ)培養(yǎng)基：RPMI-1640 培養(yǎng)基。

• 維持期完全培養(yǎng)基配方（日常傳代）：RPMI-1640 基礎(chǔ)培養(yǎng)基 加 10% 優(yōu)質(zhì)胎牛血清（FBS） 加 1% 青霉素-鏈霉素雙抗。

• 耐藥壓力維持（關(guān)鍵點）：

  • 在常規(guī)擴增與日常傳代期間，通常需要在完全培養(yǎng)基中額外添加維持濃度的紫杉醇（具體藥物濃度需嚴格遵照隨貨細胞說明書，通常在 50 nM - 100 nM 范圍，因具體克隆株耐藥指數(shù)而異），以防細胞在無藥環(huán)境下由于逆向進化而導致耐藥性發(fā)生部分退化。

  • 重要提示：在正式用于下游實驗（如 MTT 藥效檢測、Western Blot 檢測、小鼠體內(nèi)接種）前的 24 至 48 小時，必須更換為不含紫杉醇的常規(guī)完全培養(yǎng)基進行洗脫，以清除殘存藥物對后續(xù)實驗數(shù)據(jù)的背景干擾。

• 細胞解離液：0.25% Trypsin-0.02% EDTA 消化液。

• 環(huán)境參數(shù)：37 攝氏度，5% 二氧化碳，飽和濕度。

2. 冷凍細胞復蘇步驟

1. 提前在生物安全柜中配制好干凈的 T25 培養(yǎng)瓶，注入 5 - 6 mL 預熱至 37 攝氏度的常規(guī)完全培養(yǎng)基（注意：復蘇第一代時，為了保證受損細胞的恢復貼壁，千萬不要添加紫杉醇藥物）。

2. 從液氮罐中取出 4T1-Taxol 凍存管，立刻投入 37 攝氏度恒溫水浴箱中快速搖晃解凍，確保在 1 分鐘內(nèi)完全融化。

3. 用 75% 酒精噴灑消毒外壁，移入安全柜內(nèi)。

4. 用無菌移液槍吸取細胞懸液，緩慢滴加至盛有 4 mL 預熱常規(guī)完全培養(yǎng)基的 15 mL 離心管中（動作輕柔，避免物理剪切損傷）。

5. 以 1000 rpm（約 200 g）離心 4 - 5 分鐘，小心吸除含有 DMSO 的上清液。

6. 加入 1 mL 新鮮常規(guī)完全培養(yǎng)基重懸細胞沉淀，將其接種至 T25 瓶中。前后輕柔十字晃動混勻，置于孵箱中。

7. 復蘇 24 小時后，常規(guī)觀察細胞貼壁狀態(tài)。全量更換一次新鮮培養(yǎng)基以清除死細胞。待細胞完全恢復對數(shù)生長狀態(tài)（通常復蘇 2-3 天后），在下一次傳代時再重新加入含維持劑量紫杉醇的完全培養(yǎng)基。

3. 日常貼壁常規(guī)傳代操作

• 傳代時機：當細胞融合度達到 80% 左右時必須進行傳代。4T1 系列細胞生長周期極短（倍增時間通常十幾小時），絕對不能允許其長滿至 100% 連成密不透風的片狀。一旦過密，細胞會自發(fā)老齡化、大面積抱團懸浮脫落，且極易導致耐藥表型退化。

• 操作流程：

  1. 吸除細胞瓶內(nèi)的舊培養(yǎng)基，使用無菌的、不含鈣鎂離子的 PBS 緩沖液輕輕漂洗細胞表面 1 - 2 次，洗去血清。

  2. 加入適量 0.25% 胰酶消化液（T25 瓶加入 1 mL），搖晃使其覆蓋細胞層。置于 37 攝氏度孵箱（或室溫）中消化 1 - 2 分鐘。

  3. 在倒置顯微鏡下觀察。當發(fā)現(xiàn)原本鋪展的上皮樣細胞快速回縮變圓、胞間出現(xiàn)明顯裂隙、輕敲瓶壁細胞開始整體移動時，立刻加入 2 到 3 倍體積的含血清完全培養(yǎng)基以終止胰酶消化。

  4. 用移液槍在瓶壁輕輕吹打，使其徹底剝離并分散成單細胞懸液，收集懸液入管，1000 rpm 離心 5 分鐘。

  5. 棄去上清，加入含維持劑量紫杉醇的完全培養(yǎng)基。按照 1 比 6 至 1 比 8 的常規(guī)稀釋比例，接種至新的培養(yǎng)瓶中。

  6. 通常每 2 天就需傳代一次。為了防止其耐藥基因發(fā)生長期體外變異漂移，建議體外連續(xù)傳代代數(shù)嚴格控制在 15-20 代以內(nèi)使用，嚴禁無限期連續(xù)往下傳代。

4. 細胞長期保存標準

• 凍存液配方：90% 優(yōu)質(zhì)完全培養(yǎng)基（無紫杉醇） 加 10% 分析級二甲基亞砜（DMSO），或使用 95% 完全培養(yǎng)基 加 5% DMSO。

• 冷凍規(guī)范：

  1. 收集處于對數(shù)生長最旺盛期、細胞密度在 80% 左右、形態(tài)高度健康的 4T1-Taxol 細胞（處于加藥維持狀態(tài)的細胞即可）。

  2. 經(jīng)溫和消化、離心沉淀后，用配置好的無藥凍存液懸浮，調(diào)整細胞密度至 每毫升 1,500,000 到 2,000,000 個細胞。

  3. 分裝入無菌凍存管中，立刻移入標準程序降溫盒（如 Mr. Frosty），并置于 零下 80 攝氏度冰箱中過夜梯度降溫（約每分鐘降溫 1 攝氏度）。

  4. 次日，迅速將凍存管轉(zhuǎn)移入液氮罐（零下 196 攝氏度）中長期鎖死保存。嚴禁在 零下 80 度普通冰箱內(nèi)長期存放，以防長期的微小溫度波動導致細胞內(nèi)部冰晶重塑，嚴重破壞后續(xù)復蘇時的復蘇存活率及耐藥特性的維持。

Part 2 English Section

I General Information and Cell Biological Background

• Cell Line Name: 4T1-Taxol (Standardly abbreviated as 4T1/PTX, or 4T1-PR).

• Organism and Tissue Extraction Origin: Mus musculus (mouse); derived from the parental 4T1 mouse triple-negative breast cancer line in a BALB/c background, engineered via chronic stepwise escalation exposure to Paclitaxel (Taxol).

• Cell Line Establishment Background (Derivation of the Drug-Resistant Subline):The parental 4T1 lineage is a globally standardized, hyper-aggressive, and invasive human Triple-Negative Breast Cancer (TNBC) syngeneic analog.In clinical oncology, Paclitaxel (Taxol) represents a primary microtubule-stabilizing chemotherapeutic; however, long-term administration frequently induces acquired multidrug resistance. Investigators exposed parental 4T1 cultures to an escalating chemical selection pressure regimen (Stepwise escalating drug selection method) spanning multiple months, starting from nanomolar scales. Surviving drug-tolerant colonies were enriched and cloned to validate 4T1-Taxol, locking in a highly stable paclitaxel-resistant phenotype.

• Core Morphological Phenotype and Resistance Mechanisms:

  • Resistance Profile Designation: Exhibits an extreme shift in its half-maximal inhibitory concentration (IC50) index, demonstrating a multifold surge in tolerance compared to parental cells. The line shows complete evasion of paclitaxel-induced microtubule bundling, mitotic arrest, and downstream apoptotic signaling cascades.

  • Morphological Form: Adherent growth; under inverted phase-contrast microscopy, it maintains a general epithelial-like framework. However, compared to parent cells, the resistant variants typically appear enlarged, flattened, and elongated, exhibiting profound cytoskeleton remodeling and hypertrophic nuclear configurations.

  • Molecular Machinery of Evasion: Driven by high expression of cellular drug efflux pumps (such as P-glycoprotein, encoded by MDR1/ABCB1), specific structural mutations or shifts in β-tubulin isotype profiles, or hyper-activation of cell survival networks (such as the HER2/β-catenin/c-Myc signaling loops), allowing cells to bypass cell cycle surveillance hubs.

• Biosafety Matrix: Classified under Biosafety Level 1 (BSL-1) parameters.

II Strategic Research Value and Translational Fields

4T1-Taxol circumvents a critical limitation of human-derived resistant lineages—their inability to establish tumors in immunocompetent animals—making it essential for translational oncology studies:

1. High-Throughput Screening of Chemoresistance Reversers:4T1-Taxol serves as a standard screening substrate to discover "Paclitaxel sensitizers". It is used to test whether novel small-molecule kinase inhibitors, P-gp efflux pump antagonists, or bioactive natural molecules (such as green tea catechins/EGCG) can act synergistically with taxanes to restore chemotherapeutic sensitivity.

2. Syngeneic Immunocompetent Resistant CDX Modeling:This represents the primary strategic value of the line. Inoculating 4T1-Taxol into immunocompetent female BALB/c recipients (either subcutaneously or directly into the mammary fat pads) yields a 100% tumor-take profile. This system reproduces the intricate pathology of advanced, chemoresistant TNBC in humans, mimicking primary tumor progression alongside spontaneous distal spread under an intact host immune system.

3. Deciphering Metastasis Mechanics & Tumor Microenvironment (TME) Modeling:The parental 4T1 background naturally tracks multi-organ spontaneous metastasis (homing to lungs, liver, bones, and brain). Utilizing the 4T1-Taxol configuration allows investigators to determine if chemoresistance pathways accelerate Epithelial-Mesenchymal Transition (EMT) and distal migration, and to examine how chemoresistant nodes remodel the TME by exhausting effector T-cells and enriching Myeloid-Derived Suppressor Cells (MDSCs).

III Laboratory Thawing, Cultivation, Passaging, and Cryopreservation Protocols

4T1-Taxol cells proliferate rapidly with a brief doubling time and a high rate of nutrient consumption. The primary parameter of daily cultivation is maintaining the stability of the drug-resistant phenotype.

1. Growth Medium & Chemo-Pressure Maintenance Protocols

• Basal Medium: RPMI-1640 medium.

• Maintenance Complete Medium Formulation (Routine Passaging): Basal RPMI-1640 medium enriched with 10% premium Fetal Bovine Serum (FBS) and supplemented with 1% Penicillin-Streptomycin dual antibiotics.

• Drug Maintenance Control Window (Critical Protocol):

  • To secure resistance stability during routine maintenance, the complete growth medium must be spiked with a maintenance dose of Paclitaxel (ranging typically between 50 nM and 100 nM depending on specific lot specifications and target verification boundaries). Cultivating cells in a drug-free matrix for extended periods can cause gradual regression of the resistant phenotype.

  • Critical Operational Note: The maintenance medium must be evacuated and replaced with drug-free complete growth medium 24 to 48 hours prior to downstream functional assays (e.g., in vitro MTT cytotoxicity profiling, Western blotting, or live animal inoculation) to wash out residual intracellular paclitaxel and eliminate background drug interference.

• Cell Dissociation Enzyme: Standard 0.25% Trypsin-0.02% EDTA solution.

• Environmental Cultivation Constants: Incubate at 37 degrees Celsius inside a humidified atmosphere charged with 5% Carbon Dioxide.

2. Cryovial Thawing and Recovery Sequence

1. Pre-warm a pristine T25 tissue culture flask packed with 5 - 6 mL of standard drug-free complete growth medium inside the Class II Biosafety Cabinet. (Note: Do not add paclitaxel during initial recovery to prevent acute cytotoxicity while the cells are structurally fragile post-thaw).

2. Retrieve the 4T1-Taxol cryovial from liquid nitrogen storage and submerge it instantly into a 37 degrees Celsius constant-temperature water bath. Shake rapidly and continuously to secure absolute thawing within 60 seconds.

3. Decontaminate the exterior shell with 75% ethanol before transfer into the biosafety cabinet.

4. Using a sterile pipettor, smoothly extract the thawed suspension and deliver it dropwise into a 15 mL conical tube packed with 4 mL of pre-warmed drug-free complete medium. Handle gently to avoid structural cell shear stress.

5. Centrifuge the suspension at 1000 rpm (approximately 200 g) for 4 - 5 minutes at room temperature, then carefully decant the DMSO-laden supernatant.

6. Resuspend the cell sediment in 1 mL of fresh drug-free complete growth medium and transfer the entire volume into the prepared T25 flask. Distribute evenly by executing a gentle cross-shake movement and place in the incubator.

7. Inspect the adherent status approximately 24 hours post-thaw. Perform a complete medium change to remove non-adherent dead cell fragments. Once the cells regain robust log-phase division metrics (typically 2-3 days post-thaw), reintroduce the complete growth medium spiked with the maintenance dose of paclitaxel at the next passage.

3. Routine Adherent Passaging Mechanics and Maintenance

• Confluency Control Window: Subculturing routines must be initiated when monolayers achieve a target 80% confluency scale.Due to its rapid doubling cycle, never allow 4T1-Taxol sheets to achieve 100% full saturation or compact layering. Overcrowding triggers rapid cell aging, large-scale sheet detachment into floating spheres, and a structural drop in drug-resistance stability.

• Passaging Execution Steps:

  1. Aspirate the spent growth matrix and gently rinse the cell layer 1 - 2 times with sterile, calcium/magnesium-free PBS to remove all remaining serum proteins that could deactivate the trypsin.

  2. Administer a suitable volume of 0.25% Trypsin-EDTA enzyme (typically 1 mL for a T25 flask format), tilt the flask to ensure total monolayer coverage, and place inside the 37 degrees Celsius incubator for 1 - 2 minutes.

  3. Monitor cell detachment kinetics under an inverted microscope. As the epithelial-like cells round up, separate from neighbors, and slide upon gentle physical tapping of the flask wall, immediately add 2 to 3 volumes of serum-fortified complete growth medium to arrest enzymatic cleavage.

  4. Gently pipette the solution against the flask walls to rinse down remaining cells and dissociate clusters into a single-cell suspension. Transfer the suspension into a conical tube and centrifuge at 1000 rpm for 5 minutes.

  5. Discard the supernatant, resuspend the cell pellet in fresh, pre-warmed complete growth medium supplemented with the maintenance dose of paclitaxel, and inoculate into new flasks utilizing standard split ratios of 1:6 to 1:8.

  6. Execute subculturing every 2 days. To prevent genetic drift and maintain long-term phenotypic integrity, it is highly recommended to restrict in vitro expansion to under 15–20 total passages.

4. Long-Term Cryopreservation Standards

• Cryoprotectant Preservation Matrix: 90% premium complete growth medium (without paclitaxel) supplemented with 10% analytical-grade Dimethyl Sulfoxide (DMSO) (or 95% complete medium with 5% DMSO).

• Freezing Protocol Validation:

  1. Exclusively harvest healthy, log-phase cultures showing an optimal confluency of approximately 80% under standard maintenance drug conditions.

  2. Post-enzymatic treatment and centrifugation, adjust the cell concentration inside the formulated drug-free cryoprotectant matrix to a target range of 1,000,000 to 2,000,000 cells per milliliter.

  3. Dispense the suspension into sterile cryovials, insert them immediately into a controlled-rate freezing device (e.g., Mr. Frosty), and place into a minus 80 degrees Celsius freezer overnight to achieve steady gradient cooling (approximately 1 degree Celsius per minute).

  4. The following day, swiftly transfer the frozen cryovials into liquid nitrogen storage tanks (minus 196 degrees Celsius) for definitive long-term preservation. Do not store vials indefinitely inside a minus 80 degrees Celsius freezer; minor temperature oscillations can compromise post-thaw recovery rates and lead to the degradation of resistant traits.

BioVector NTCC質(zhì)粒載體菌株細胞蛋白抗體基因保藏中心

電話:400-800-2947

工作QQ/微信同號:1843439339

網(wǎng)址http://www.nedfriskphoto.com